tiprankstipranks
Advertisement
Advertisement

AGIO Stock Latest News

Agios Pharmaceuticals price target raised to $36 from $31 at JPMorgan
The FlyAgios Pharmaceuticals price target raised to $36 from $31 at JPMorgan
4d ago
AGIO
Agios Pharmaceuticals price target raised to $36 from $31 at JPMorgan
PremiumThe Fly
Agios Pharmaceuticals price target raised to $36 from $31 at JPMorgan
4d ago
AGIO
Agios Pharmaceuticals price target raised to $32 from $28 at Goldman Sachs
PremiumThe Fly
Agios Pharmaceuticals price target raised to $32 from $28 at Goldman Sachs
9d ago
AGIO
Leerink says Agios’ filing reinforces FDA flexibility ahead of Fulcrum update
PremiumThe Fly
Leerink says Agios’ filing reinforces FDA flexibility ahead of Fulcrum update
10d ago
AGIO
FULC
Agios Pharmaceuticals: Mitapivat’s Accelerated Approval Path and De-Risked Sickle Cell Opportunity Support Buy Rating
PremiumRatings
Agios Pharmaceuticals: Mitapivat’s Accelerated Approval Path and De-Risked Sickle Cell Opportunity Support Buy Rating
10d ago
AGIO
Agios up 13% at $33.50 after announcing pursuit of approval for mitapivat
PremiumThe FlyAgios up 13% at $33.50 after announcing pursuit of approval for mitapivat
10d ago
AGIO
Agios Pharmaceuticals to pursue U.S. accelerated approval for mitapivat
Premium
The Fly
Agios Pharmaceuticals to pursue U.S. accelerated approval for mitapivat
10d ago
AGIO
Citi ups Agios target, opens ‘upside 90-day catalyst watch’
Premium
The Fly
Citi ups Agios target, opens ‘upside 90-day catalyst watch’
1M ago
AGIO
Agios Pharmaceuticals Pyrukynd approved for adults in UAE
PremiumThe Fly
Agios Pharmaceuticals Pyrukynd approved for adults in UAE
1M ago
AGIO
Agios Pharmaceuticals Signals Confident Path After AQVESME Win
PremiumCompany Announcements
Agios Pharmaceuticals Signals Confident Path After AQVESME Win
2M ago
AGIO
Regulatory Delays Threaten Agios Pharmaceuticals’ Drug Pipeline, Costs and Revenue Outlook
PremiumCompany Announcements
Regulatory Delays Threaten Agios Pharmaceuticals’ Drug Pipeline, Costs and Revenue Outlook
2M ago
AGIO
Agios Pharmaceuticals Signals Confident Path After AQVESME Win
PremiumCompany Announcements
Agios Pharmaceuticals Signals Confident Path After AQVESME Win
2M ago
AGIO
Buy Rating Backed by Strong Q4 Execution, Early Aqvesme Momentum, and Multi-Asset Clinical Catalyst Upside
PremiumRatingsBuy Rating Backed by Strong Q4 Execution, Early Aqvesme Momentum, and Multi-Asset Clinical Catalyst Upside
2M ago
AGIO
Agios Pharmaceuticals files automatic mixed securities shelf
Premium
The Fly
Agios Pharmaceuticals files automatic mixed securities shelf
2M ago
AGIO
Agios Pharmaceuticals: Early Aqvesme Traction and REMS-Driven Uptake Support Robust Mitapivat Growth and Buy Rating
Premium
Ratings
Agios Pharmaceuticals: Early Aqvesme Traction and REMS-Driven Uptake Support Robust Mitapivat Growth and Buy Rating
2M ago
AGIO
Agios Pharmaceuticals reports Q4 revenue $20.0M, consensus $12.06M
PremiumThe Fly
Agios Pharmaceuticals reports Q4 revenue $20.0M, consensus $12.06M
2M ago
AGIO
JPMorgan large/SMid cap biotech analysts hold analyst/industry conference call
PremiumThe Fly
JPMorgan large/SMid cap biotech analysts hold analyst/industry conference call
2M ago
AGIO
FULC
AGIO Earnings Report this Week: Is It a Buy, Ahead of Earnings?
PremiumPre-Earnings
AGIO Earnings Report this Week: Is It a Buy, Ahead of Earnings?
2M ago
AGIO
Agios Expands Rare-Disease Pipeline With New Phase 1b PKU Study of AG-181
PremiumCompany Announcements
Agios Expands Rare-Disease Pipeline With New Phase 1b PKU Study of AG-181
2M ago
AGIO
Vorasidenib’s Real-World Test in Germany: What Agios Investors Should Watch
PremiumCompany AnnouncementsVorasidenib’s Real-World Test in Germany: What Agios Investors Should Watch
3M ago
AGIO
Agios Pharma Sets 2026 Strategic Priorities After AQVESME Approval
Premium
Company Announcements
Agios Pharma Sets 2026 Strategic Priorities After AQVESME Approval
3M ago
8K
AGIO
Agios Pharmaceuticals outlines 2026 strategic priorities
Premium
The Fly
Agios Pharmaceuticals outlines 2026 strategic priorities
3M ago
AGIO

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >